Drug Database
FE

fentanyl (Fentanyl Dura / fentanyl, Lavipharm / fentanyl, Recordati)

✓ Approved

Lavipharm · OPRD1 · Small Molecule

What is fentanyl?

fentanyl is a small molecule developed by Lavipharm. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesFentanyl Dura, fentanyl, Lavipharm, fentanyl, Recordati
CompanyLavipharm
Drug ClassSmall Molecule
Molecular TargetOPRD1, OPRK1, OPRM1
RouteTransdermal
StatusApproved

Mechanism of Action

Molecular Targets

fentanyl acts on 3 molecular targets:

OPRD1opioid receptor delta 1 (DOR, OPRD)
OPRK1opioid receptor kappa 1 (KOR1, OPRK)
OPRM1opioid receptor mu 1 (MOR1, LMOR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fentanyl is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved

Related Research Articles

PubMedFrontiers in physiology2026-09-19

A model to simulate cardio-respiratory responses to fentanyl analgesia after traumatic injury.

Kurian Varghese V, Jin Xin X, Wallqvist Anders A, Reifman Jaques J et al.

Prehospital pain management is challenging and is expected to become even more complex in future large-scale combat operations, where mass-casualty events and evacuation delay may be inevitable. An improved understanding of how analgesic drugs affect the physiological response of trauma patients can enhance treatment efficacy of combat casualties. We previously developed and validated a cardio-respiratory (CR) model for humans that accounts for vital-sign responses to hemorrhagic injuries, resuscitation with six fluid types, airway obstruction, and ketamine analgesia. Here, we extended the model to include the effect of fentanyl on vital signs by integrating existing fentanyl pharmacokinetic-pharmacodynamic models with the neuronal controller of the model. We calibrated and validated the extended model using experimental data from eight studies involving intravenous fentanyl administration (0.71-50.00 μg/kg) to healthy humans and swine with hemorrhagic injury. The model predictions reasonably captured the trend of the experimental data, with root mean square errors (RMSEs) between model predictions and measured data of 0.83 L/min for minute ventilation (MV), 1.20 mmHg for end-tidal carbon dioxide, 0.09 L for tidal volume, and 1.61 mmHg for mean arterial pressure, all of which were within 3-12% of their baseline values. For plasma fentanyl concentration, we obtained RMSEs of 0.79 μg/L in humans and 25.83 μg/L in swine. In simulations, we observed that as hemorrhage increased from 0 to 40% of blood volume, the fentanyl-induced decrease in MV increased from 19 to 34% of its baseline value prior to administration due to reduced fentanyl clearance. Similarly, in simulations of airway obstruction, the fentanyl-induced decrease in MV was 26% of its baseline value after a 100% obstruction compared to only 19% for a no-obstruction condition. Given that most combat casualties receive either fentanyl or ketamine for pain management, the ability to predict and quantify the physiological effects of these drugs will allow us to generate relevant synthetic datasets of diverse battlefield scenarios.

PubMedProgress in transplantation (Aliso Viejo, Calif.)2026-09-18

Association Between Early Perioperative Fentanyl Exposure and Dose-Normalized Tacrolimus Exposure After Kidney Transplantation.

Abe Yohei Y, Kato Takuma T, Kaji Asuka A, Harada Satoshi S et al.

IntroductionTacrolimus exposure varies early after kidney transplantation, and perioperative factors may complicate therapeutic drug monitoring. Fentanyl is commonly used perioperatively, but its association with dose-normalized tacrolimus exposure is unclear. Project Aims or Questions: This study evaluated whether early perioperative fentanyl exposure was associated with dose-normalized tacrolimus exposure during the first week after kidney transplantation.DesignThis single-center retrospective program evaluation included 43 adult living-donor kidney transplant recipients who received perioperative fentanyl and had evaluable tacrolimus trough concentrations and corresponding oral daily doses. Cumulative fentanyl dose was the conventional exposure measure; body surface area-normalized and patient-controlled analgesia-administered volume measures were exploratory. The outcome was the log-transformed tacrolimus trough concentration divided by the daily tacrolimus dose. Repeated measurements were analyzed using linear mixed models adjusted for clinical covariates.ResultsThe conventional cumulative fentanyl dose through postoperative day 1 was associated with 22.7% higher dose-normalized tacrolimus exposure per 1 standard deviation increase, 95% confidence interval 4.4% to 44.1%, P = .013. In exploratory analyses, body surface area-normalized cumulative exposure through postoperative day 1 had the strongest association, a 24.9% increase, 95% confidence interval 7.3% to 45.4%, P = .004. Exposure through postoperative day 2 showed weaker, nonsignificant associations.ConclusionEarly perioperative fentanyl exposure, particularly cumulative exposure through postoperative day 1, was associated with higher dose-normalized tacrolimus exposure during the first postoperative week after kidney transplantation. These findings support contextual interpretation of early tacrolimus monitoring while recognizing confounding by clinical status and the exploratory nature of body surface area-normalized findings.

PubMedHeart & lung : the journal of critical care2026-09-18

Comparison of analgesic efficacy of dexamethasone and dexmedetomidine as an adjuvant to local anaesthetic in transversus thoracic muscle plane block in adult patients undergoing median sternotomy: A randomised controlled trial.

Kumari Poonam P, Jha Lalit L, Kumar Amarjeet A, Sinha Chandni C et al.

Post-sternotomy pain contributes significantly to delayed recovery following cardiac surgery. The transversus thoracic muscle plane block (TTPB) is a recently described regional anaesthetic technique that provides analgesia to the anterior chest wall. The addition of adjuvants such as dexamethasone and dexmedetomidine may enhance the analgesic efficacy of TTPB. This study compared the analgesic efficacy of dexamethasone and dexmedetomidine as adjuvants to bupivacaine for TTPB in patients undergoing median sternotomy. 66 adult patients (ASA I-III) scheduled for cardiac surgery via median sternotomy were recruited for this randomised trial. Following induction of anaesthesia, all patients received bilateral TTPB and were allocated to three groups: dexamethasone (0.25 % bupivacaine + 8 mg dexamethasone), dexmedetomidine (0.25 % bupivacaine + 1 µg/kg dexmedetomidine), and a control group (0.25 % bupivacaine alone). The primary outcome was the time to first rescue analgesia following extubation. Secondary outcomes included 24-hour postoperative fentanyl consumption, intraoperative fentanyl requirement, pain scores, extubation time, patient satisfaction, and adverse events. Time to first rescue analgesia was significantly longer in the dexmedetomidine group than in the dexamethasone and control groups (P 0.001). Twenty-four-hour postoperative fentanyl consumption was significantly lower in both adjuvant groups than in the control group (P < 0.001). Pain scores were consistently lower with dexmedetomidine and dexamethasone groups. Extubation time and intraoperative fentanyl consumption were comparable among the three groups (P > 0.05). Both dexamethasone and dexmedetomidine improved TTPB analgesia. Dexmedetomidine significantly prolonged the duration of analgesia, whereas 24-hour postoperative opioid consumption was comparable between the adjuvant groups.

PubMedSe pu = Chinese journal of chromatography2026-09-18

[Determination of 15 fentanyl analogs and amphetamine-type stimulants in hair by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry].

Wei Qi Q, Su Fu-Hai FH, Zhu Xin X

Drug abuse is a major global public health problem. Fentanyl analogs and amphetamine-type stimulants (ATS) are widely abused worldwide. Hair analysis can trace drug use history over months. This technique has unique advantages in forensic toxicology. However, its application is limited by a lack of matrix-certified reference materials (CRMs). At present, the existing CRMs are unable to simultaneously cover both fentanyl analogs and amphetamine-type stimulants. This study established a hair sample preparation method based on a water‑dimethyl sulfoxide‑hydrochloric acid soaking approach, targeting 15 analytes (nine fentanyl analogs and six ATS). The soaking time was systematically investigated. Drug incorporation into hair reached a maximum at 24 days. A slight decrease was observed at 25 days. This decrease may result from desorption and solvent-induced structural changes in keratin. Therefore, 24 days was selected as the optimal soaking time. Preparation experiments demonstrated that 14 of the 15 drugs were successfully embedded into the hair matrix. This study also applied a dual-platform quantitative strategy for certification. The two platforms were liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS). Cross-validation between the two platforms improved the reliability of certified values. Sample pretreatment conditions were optimized using Box-Behnken response surface methodology. Four factors were investigated: extraction temperature, extraction time, liquid-to-solid ratio, and hydrochloric acid concentration. The effects of the four factors on extraction efficiency followed a decreasing order: extraction temperature>extraction time>liquid-to-solid ratio>hydrochloric acid concentration. The optimal extraction conditions were as follows: extraction temperature 40 ℃, extraction time 50 min, liquid-solid ratio 100∶1 (mL/g), and hydrochloric acid concentration 0.01 mol/L. Method validation was performed according to international guidelines. For LC-MS/MS, the limits of detection (LODs) and quantification (LOQs) were 0.05 pg/mg and 0.25 pg/mg, respectively. For GC-MS, the LODs and LOQs were 0.02 ng/mg and 0.08 ng/mg, respectively. Good linearities were obtained for all 15 drugs. Correlation coefficients (r) were greater than 0.999 for both platforms. Good linearities were obtained for all 15 analytes on both platforms with correlation coefficients >0.999 over the respective concentration ranges Intra-day precisions (n=6) were evaluated as relative standard deviations (RSDs). Inter-day precision (n=30 over 5 days) was also calculated. For 14 drugs (except amphetamine), RSD values ranged from 0.2% to 9.4%. All RSDs were below 10%, indicating good repeatability and intermediate precision. Stability of hair extracts was assessed at 1, 24, 48, 72, and 96 h at room temperature. The extracts were stable for at least 96 h when stored at room temperature, with RSDs below 6.0% for LC-MS/MS and below 10% for GC-MS. Recovery tests were performed at three quality control levels (low, medium, high). For LC-MS/MS, average recoveries ranged from 84.46% to 116.4% (n=3). For GC-MS, average recoveries ranged from 85.50% to 116.4% (n=3). All RSDs were below 15%. Matrix effects (MEs) were evaluated by comparing matrix-matched standards with solvent standards. ME values between 80% and 120% (n=3) were observed for both platforms. These results indicate negligible ion suppression or enhancement. Homogeneity of the prepared hair reference material was assessed. The results show that the uniformity of the hair samples is good. The contents of the 14 drugs in the prepared hair samples were determined. For LC-MS/MS, the values ranged from 1.012 ng/mg to 7.830 ng/mg. For GC-MS, the values ranged from 1.087 ng/mg to 7.712 ng/mg. Amphetamine was not detected by either platform, likely due to its high polarity and weak binding to keratin. Most drugs showed good agreement between the two platforms. Relative deviations were below 10% for most analytes. However, methamphetamine showed a deviation of -12%. This may be due to matrix effects in LC-MS/MS. The GC-MS results for methamphetamine were more robust. The dual-platform approach allowed cross-validation and enhanced the reliability of the certified values. In conclusion, a dual-platform method based on LC-MS/MS and GC-MS was successfully applied to certify a new hair matrix reference material. The cross-validation strategy enhances the accuracy and traceability of the certified values. This work provides a valuable tool for quality control in forensic toxicology laboratories. The prepared reference material and validated method will facilitate inter-laboratory comparisons. They will also support the monitoring of drug abuse in forensic and clinical settings.

PubMedMolecular pharmacology2026-09-18

High potency μ-opioid receptor agonists engage sodium-bound receptor states.

Powell Alexander J AJ, Griggs Nicholas W NW, Iñiguez-Lluhí Jorge A JA, Mosberg Henry I HI et al.

The simple 2-state conformational selection model of G protein-coupled receptor activation suggests that, by binding to a high-affinity state, an agonist shifts receptor equilibrium in favor of active state (R∗) conformations that recruit heterotrimeric G proteins over inactive (R) conformations. Agonist binding affinity at the μ-opioid receptor is reduced in the presence of Na+ ions, which stabilize R conformations. The binding of higher efficacy opioid agonists, such as [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin and fentanyl, is more sensitive to Na+ ions than lower efficacy ligands. However, the binding of the highly potent agonists etorphine and dihydroetorphine is less sensitive to Na+ ions than expected, such that the prevailing models fail to explain their pharmacology. To understand this discrepancy, experiments were performed to evaluate the binding properties and G protein activation of several high-affinity, high-potency agonists, including carfentanil, etonitazene, and several peptidomimetics in comparison to [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin, Met-enkephalin, fentanyl, and morphine in the presence of Na+ or K+ ions. Several very potent agonists retained high-affinity and potency in both ionic conditions, whereas the standard agonists displayed enhanced binding and signaling only in the presence of K+ ions. Comparison of the difference in binding affinity with degree of agonism afforded a negative correlation in which several ligands with a very high degree of agonism were least sensitive to Na+ ions. These data suggest that select highly potent μ-opioid receptor agonists have high-affinity for Na+ bound receptor states and shift the receptors into active conformations that efficiently couple to G protein. SIGNIFICANCE STATEMENT: The theory of conformational selection suggests that agonists bind to active states (R∗) of G protein-coupled receptors, including the μ-opioid receptor, to shift the receptor equilibrium in favor of R∗ over inactive states (R). This study demonstrates that ligands with very high-affinity and potency at the μ-opioid receptor can engage low-affinity Na+-bound receptor states (R) and convert these to active R∗ states that efficiently couple to G protein, suggesting a conformational induction model.

PubMedThe American journal of drug and alcohol abuse2026-09-18

Dying in the year after surviving: a perspective on elevated all-cause mortality among opioid overdose survivors.

Raffa Robert B RB, Dahan Albert A, Pergolizzi Joseph V JV, Vortsman Eugene E et al.

It has been reported that opioid overdose survivors who had a prior non-fatal opioid overdose have a substantially elevated one-year all-cause mortality compared to first-time overdose survivors. The objective of this Perspective was to construct a framework for assessing the observed elevated post-overdose one-year mortality burden. We reviewed published peer-reviewed literature in the English language identified through PubMed-MEDLINE, with supplemental searches of JAMA Network, the New England Journal of Medicine (NEJM), and federal surveillance data (e.g. CDC and SAMHSA). References were selected for relevance, prioritizing 2020-2026, and were used as direction to additional sources of material. It was found that elevated one-year mortality among prior overdose survivors reflects at least six interacting mechanistic realms: (1) cumulative hypoxic-ischemic organ injury, including hippocampal atrophy and leukoencephalopathy; (2) cardiopulmonary toxicity and opioid withdrawal-induced cardiomyopathy; (3) opioid-induced immunosuppression with heightened vulnerability to infective endocarditis and sepsis; (4) neuropsychological sequelae including executive dysfunction, amnestic syndrome, and suicidality; (5) opioid tolerance compounded by fentanyl-specific pharmacotoxicology; and (6) sociostructural determinants such as housing instability, racial disparities, and treatment gap with some high-risk populations, including Medicare disability beneficiaries, showing that fewer than 5% received medication for opioid use disorder (MOUD) after nonfatal overdose. Therefore, we propose that elevated postoverdose one-year mortality is not simply a marker of substance-use severity, but also a multi-organ, multi-system consequence of repeated physiological insult, neuropsychological injury, and socioeconomic circumstance.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about fentanyl